The Need For Speed: Early-Stage Dosage Form Development

Speed is critical in early-stage drug development, but moving quickly requires the right balance between flexibility, scientific rigor, and future scalability. For oral therapies entering first-in-human studies, dosage form development is focused on enabling rapid clinical evaluation while accommodating a range of dose levels and evolving study requirements.

Early formulation decisions are often shaped by the physical and chemical properties of the active pharmaceutical ingredient (API). While simple approaches such as powder-in-capsule formulations can accelerate timelines, challenges related to flowability, solubility, stability, or bioavailability may require more advanced formulation strategies. Understanding these characteristics early through robust CMC studies and forced degradation testing helps identify potential development risks before they become costly obstacles.

As accelerated clinical programs become more common, thoughtful early-stage dosage form design can support both rapid trial initiation and smoother progression into later development stages. Read the full article to learn how formulation teams navigate the tradeoffs between speed, flexibility, and long-term success.